Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma

NCT02113007 is registered in ClinicalTrials.gov with SCRI Development Innovations, LLC as lead sponsor.

NCT NCT02113007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02113007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma
Lead sponsor
SCRI Development Innovations, LLC
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2014
Completion date
February 29, 2016
Enrollment
2 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

primary central nervous system lymphoma